RE:RE:RE:RE:RE:RE:pre-BTD and BTDDJDawg wrote: I totally agree with the disconnect between the CR numbers and the money raising success/lack of it. It is one reason I am so grateful that the science clinical data is gathered by scientist who don't actually work for TLT. They gathered the data that is so promising and it gives me more confidence in the science compared to data that only comes from the company lab.
I really wish I could explain why so hard to raise money.
I think most of us of read up on the science and believe in that. But if you didn't know that MacFarland's science was so strong and was, in a way separate from the company's reputation, you would have reservations about it. Due to:
- RDW's OSC ruling
- Vera's in and out
- Shawn and Trikola's in and out
- Why still on venture exchange if so good
- Why still so small if so good
- RDW suing internet posters.
These kind of topics make the company look so poor that you would have to really like the science to see past it and want to invest. That is my best guess.
I also believe that they have never worked hard to get American big pockets in (till now, maybe) as I think RDW likes to be in control of the journey.
In my opinion, everything you listed in that post, and likely far more behind the scenes that we're not privy to, is exactly why they have had such difficulty raising funds, forcing investors to endure this begging bowl go it alone dilutive path.
To see such an enormous divergence between the incredible science along with the impressive CR data this far advanced in a pivotal trial vs.complete market disinterest and an assigned paltry valuation is beyond frustrating oftentimes.
My hope is the offering is fully subscribed shortly and that with 2024 completely funded, they can focus on achieving the many significant milestones the science, the patients and us investors all deserve!